ATE445609T1 - Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen - Google Patents

Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen

Info

Publication number
ATE445609T1
ATE445609T1 AT06720513T AT06720513T ATE445609T1 AT E445609 T1 ATE445609 T1 AT E445609T1 AT 06720513 T AT06720513 T AT 06720513T AT 06720513 T AT06720513 T AT 06720513T AT E445609 T1 ATE445609 T1 AT E445609T1
Authority
AT
Austria
Prior art keywords
glucagone
preparation
receptor antagonists
compounds
therapeutic applications
Prior art date
Application number
AT06720513T
Other languages
English (en)
Inventor
Mark Chappell
Scott Conner
Allie Tripp
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694345&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE445609(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE445609T1 publication Critical patent/ATE445609T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06720513T 2005-02-11 2006-02-09 Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen ATE445609T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65249205P 2005-02-11 2005-02-11
PCT/US2006/004461 WO2006086488A2 (en) 2005-02-11 2006-02-09 Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
ATE445609T1 true ATE445609T1 (de) 2009-10-15

Family

ID=36694345

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06720513T ATE445609T1 (de) 2005-02-11 2006-02-09 Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen

Country Status (25)

Country Link
US (1) US8084489B2 (de)
EP (1) EP1856090B1 (de)
JP (1) JP4988604B2 (de)
KR (1) KR20070104409A (de)
CN (1) CN101115735B (de)
AT (1) ATE445609T1 (de)
AU (1) AU2006213894B2 (de)
BR (1) BRPI0607015A2 (de)
CA (1) CA2597073C (de)
CR (1) CR9304A (de)
CY (1) CY1109624T1 (de)
DE (1) DE602006009773D1 (de)
DK (1) DK1856090T3 (de)
EA (1) EA200701705A1 (de)
ES (1) ES2332470T3 (de)
IL (1) IL184932A0 (de)
MA (1) MA29432B1 (de)
MX (1) MX2007009661A (de)
NO (1) NO20074567L (de)
PL (1) PL1856090T3 (de)
PT (1) PT1856090E (de)
SI (1) SI1856090T1 (de)
TN (1) TNSN07313A1 (de)
WO (1) WO2006086488A2 (de)
ZA (1) ZA200706354B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551015A (en) * 2004-06-14 2010-07-30 Lilly Co Eli Glucagon receptor antagonists, preparation and therapeutic uses
AU2008212816B2 (en) 2007-02-09 2014-08-07 Metabasis Therapeutics, Inc. Novel antagonists of the glucagon receptor
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2326618B1 (de) 2008-08-13 2014-10-15 Metabasis Therapeutics, Inc. Glucagon-antagonisten
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
SG191040A1 (en) 2010-12-23 2013-08-30 Pfizer Glucagon receptor modulators
PE20140253A1 (es) 2011-02-08 2014-03-09 Pfizer Moduladores del receptor de glucagon
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2734503B1 (de) 2011-07-22 2015-09-16 Pfizer Inc. Chinolinylglucagonrezeptor- modulatoren
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
EP3350200A4 (de) 2015-09-18 2019-03-27 Wake Forest University Health Services Angiotensin (1 7)-analoga und assoziierte verfahren
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
EP3506940A1 (de) 2016-08-30 2019-07-10 Regeneron Pharmaceuticals, Inc. Verfahren zur behandlung schwerer insulinresistenz durch interferenz mit glucagonrezeptorsignalisierung
WO2018075792A1 (en) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
CA3071387A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
CN111954560A (zh) 2018-02-13 2020-11-17 配体药物公司 胰高血糖素受体拮抗剂
JP2023506917A (ja) 2019-12-20 2023-02-20 バイエル・アクチエンゲゼルシヤフト 置換チオフェンカルボキサミド、チオフェンカルボン酸およびその誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365622A1 (en) 2001-12-03 2003-06-17 Novo Nordisk A/S Novel glucagon antagonists
EP1519723A1 (de) 2002-06-27 2005-04-06 Novo Nordisk A/S Glucagon antagonisten/inverse agonisten
EP1758859B1 (de) 2004-05-28 2013-07-17 Eli Lilly And Company Glucagonrezeptorantagonisten, herstellung und therapeutische verwendungen
NZ551015A (en) 2004-06-14 2010-07-30 Lilly Co Eli Glucagon receptor antagonists, preparation and therapeutic uses

Also Published As

Publication number Publication date
CN101115735B (zh) 2013-01-09
MA29432B1 (fr) 2008-05-02
EP1856090A2 (de) 2007-11-21
CY1109624T1 (el) 2014-08-13
NO20074567L (no) 2007-11-08
AU2006213894B2 (en) 2011-12-08
JP4988604B2 (ja) 2012-08-01
WO2006086488A2 (en) 2006-08-17
BRPI0607015A2 (pt) 2009-12-01
MX2007009661A (es) 2007-09-25
IL184932A0 (en) 2007-12-03
CR9304A (es) 2008-03-31
CA2597073C (en) 2014-11-25
EP1856090B1 (de) 2009-10-14
JP2008530102A (ja) 2008-08-07
PT1856090E (pt) 2009-11-18
KR20070104409A (ko) 2007-10-25
CN101115735A (zh) 2008-01-30
ZA200706354B (en) 2008-11-26
WO2006086488A3 (en) 2006-12-14
US20100137417A1 (en) 2010-06-03
DE602006009773D1 (de) 2009-11-26
EA200701705A1 (ru) 2008-02-28
SI1856090T1 (sl) 2010-02-26
AU2006213894A1 (en) 2006-08-17
US8084489B2 (en) 2011-12-27
TNSN07313A1 (en) 2008-12-31
PL1856090T3 (pl) 2010-02-26
DK1856090T3 (da) 2009-11-30
CA2597073A1 (en) 2006-08-17
ES2332470T3 (es) 2010-02-05

Similar Documents

Publication Publication Date Title
ATE445609T1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
DK1758853T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
ATE454372T1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
DK1861360T3 (da) Pyrrolidin-derivater som histamin-H3-receptorantagonister
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1856090

Country of ref document: EP